Aims In the Digitalis Investigation Group (DIG) trial, digoxin reduced mortality or
hospitalization due to heart failure (HF) in several pre‐specified high‐risk subgroups of HF …

BACKGROUND: In heart failure (HF), digoxin at low serum digoxin concentrations (SDC)
reduces all-cause mortality and HF hospitalizations. However, the effects of digoxin on other …

Aims To determine the effects of digoxin on all-cause mortality and heart failure (HF)
hospitalizations, regardless of ejection fraction, accounting for serum digoxin concentration …

In the Digitalis Investigation Group trial, digoxin-associated decrease in the combined end
point of heart failure (HF) hospitalization or HF mortality was significant in systolic but not in …

BACKGROUND: Digoxin has been shown to reduce heart failure (HF) hospitalizations with
no overall effect on mortality in HF patients. We used cluster analysis to delineate the clinical …

Background: The role of digoxin in the prognosis of patients with heart failure (HF) remains
unclear. Aims: To evaluate the relationship of commencing treatment with digoxin (CTDig) …

Abstract Aims The Digitalis Investigation Group (DIG) trial, the only large randomized trial of
digoxin in heart failure, reported a neutral effect on mortality and a significant reduction in …

Several retrospective studies have raised concerns regarding digoxin therapy in select
subgroups of heart failure patients. To assess the impact of digoxin therapy on outcomes in …

Background The role of cardiac glycosides in treating patients with chronic heart failure and
normal sinus rhythm remains controversial. We studied the effect of digoxin on mortality and …

Discontinuation of digoxin is associated with worsening heart failure (HF) symptoms.
However, the long-term effects of discontinuation of digoxin therapy on mortality and …